Abstract | OBJECTIVES: METHODS: The design was double-blind crossover of clotiapine vs chlorpromazine. No washout was necessary from previous neuroleptic treatment, and flexible overlap with the study medication was individualized for each patient. Patients were treated after reaching neuroleptic monotherapy for 3 months with clotiapine and 3 months with chlorpromazine, in random order. Medication was supplied in identical capsules of 100 mg chlorpromazine or 40 mg of clotiapine. Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) were rated every 2 weeks and Nurse's Observation Scale for Inpatient Evaluation (NOSIE) every month. RESULTS: Fifty-eight patients were randomized. Forty-three patients completed at least one phase of the study, and thirty-three completed both phases. Because of the small number of hostel patients and the very high dropout rate in the hostel patients, data analysis was done separately for inpatients and hostel patients. Clotiapine was significantly superior to chlorpromazine in 26 inpatients completing the crossover, on the PANSS, NOSIE and CGI. Clotiapine was also superior to chlorpromazine in an analysis of the parallel inpatient groups in the first three months before the crossover. CONCLUSION:
|
Authors | Vadim Geller, Igor Gorzaltsan, Tatiana Shleifer, R H Belmaker, Yuly Bersudsky |
Journal | Schizophrenia research
(Schizophr Res)
Vol. 80
Issue 2-3
Pg. 343-7
(Dec 15 2005)
ISSN: 0920-9964 [Print] Netherlands |
PMID | 16126373
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Dibenzothiazepines
- Chlorpromazine
- clothiapine
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Chlorpromazine
(therapeutic use)
- Chronic Disease
- Cross-Over Studies
- Dibenzothiazepines
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Schizophrenia
(diagnosis, drug therapy)
- Severity of Illness Index
|